Physician profile
Bashir Ahmed
NPI 1861466641
$330.60
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.63 · 2020: $65.80 · 2021: $123 · 2022: $70.28.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $68.96 | 2021-2022 | |
| Gilead Sciences, INC. | $43.45 | 2019 | |
| Biogen, INC. | $42.10 | 2021 | |
| Allergan, INC. | $41.53 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $28.19 | 2020-2021 | |
| Daiichi Sankyo INC. | $22.35 | 2020 | |
| Pfizer INC. | $21.14 | 2021 | |
| Eyevance Pharmaceuticals LLC | $18.54 | 2021 | |
| Hikma Pharmaceuticals USA | $18.54 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.02 | 2020 | |
| Medtronic, INC. | $12.78 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashir Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.